Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2 CAD | +2.56% | -4.76% | +42.86% |
19/04 | Pharmala Biotech Completes $750,000 Private Placement, Debt Settlement | MT |
19/04 | Pharmala Biotech Holdings Inc. announced that it has received CAD 0.75 million in funding | CI |
Business Summary
Sales per Business
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Engineering-grade (Non-GMP) Product
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | +581.44% |
Sales per region
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Canada
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | +581.44% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Nick Kadysh
CEO | Chief Executive Officer | 38 | 21/21/21 |
Carmelo Marrelli
DFI | Director of Finance/CFO | 53 | 22/21/22 |
Harpreet Kaur
CTO | Chief Tech/Sci/R&D Officer | - | - |
Shane Morris
COO | Chief Operating Officer | 49 | 22/21/22 |
David Purcell
SAM | Sales & Marketing | - | 14/22/14 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Kevin Roy
BRD | Director/Board Member | - | 04/22/04 |
Director/Board Member | 62 | 21/21/21 | |
Jodi Butts
CHM | Chairman | 51 | 21/21/21 |
Nick Kadysh
CEO | Chief Executive Officer | 38 | 21/21/21 |
Perry Tsergas
BRD | Director/Board Member | 39 | 21/21/21 |
Fraser MacDonald
BRD | Director/Board Member | 38 | 21/21/21 |
Harriet de Wit
BRD | Director/Board Member | 76 | 21/21/21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 86,907,552 | 81,657,052 ( 93.96 %) | 0 | 93.96 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+42.86% | 12.32M | |
-1.71% | 104B | |
+3.38% | 97.47B | |
+5.44% | 22.25B | |
-13.78% | 21.68B | |
-9.63% | 18.2B | |
-39.98% | 17.02B | |
-11.26% | 16.36B | |
+7.00% | 14.39B | |
+38.12% | 12.37B |
- Stock Market
- Equities
- MDMA Stock
- Company Pharmala Biotech Holdings Inc.